ब्यूटाल्बिटल, पैरासिटामोल और कैफीन और वैल्प्रोइक एसिड का इंटरैक्शन

All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity.

Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate.

There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum concentrations.

Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate.

Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients.

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.